Drug Pharmacologya | Doses | Route | Strain/Species | Sex | ICSS Procedureb | Drug Effectc | Dependent Measure | Reference | ||
---|---|---|---|---|---|---|---|---|---|---|
Drug Name | Mechanism | Structure | Parameter | |||||||
mg/kg | ||||||||||
Nicotine | nAChR agonist | 0.025–0.8 | s.c. | Long Evans rat | Male | Hybrid | Frequency | Mixed | ↓θ0 | Bauco and Wise, 1994 |
Nicotine | nAChR agonist | 0.06–1.0 | s.c. | F-344 rat | Male | Discrete trial | Amplitude | Facilitation | ↓CIT | Huston-Lyons and Kornetsky, 1992 |
Pentobarbital | GABAA + allosteric modulator | 2.5–10 | i.p. | Long Evans rat | Male | Hybrid | Frequency | Facilitation | ↓M50 | Bossert and Franklin, 2003 |
Diazepam | GABAA + allosteric modulator | 0.5–4.0 | i.p. | C57Bl6/J mouse | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Straub et al., 2010 |
Toluene. | GABAA + allosteric modulator/NMDA ant | 480–5000 ppm | C57Bl6/J mouse | Male | Hybrid | Frequency | Mixed | ↓M50 ↑↓rate | Tracy et al., 2014 | |
Phencyclidine | NMDA antagonist | 0.5–5.0 | i.p. | CDF rat | Male | Discrete trial | Amplitude | Facilitation | ↓CIT | Kornetsky et al., 1979 |
Phencyclidine | NMDA antagonist | 0.3–5.6 | i.p. | Wistar rat | Male | Discrete trial | Amplitude | No effect | Bespalov et al., 1999 | |
Phencyclidine | NMDA antagonist | 2.5 and 5.0 | i.p. | Long Evans rat | Male | Hybrid | Frequency | Mixed | ↓θ0 ↑↓rate | Carlezon and Wise, 1993b |
MK801 | NMDA antagonist | 0.01–0.3 | i.p. | Lister rat | Male | Free operant | Mixed | ↑↓rate | Herberg and Rose, 1989 | |
MK801 | NMDA antagonist | 0.032–0.32 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Mixed | ↑↓rate | Hillhouse et al., 2014 |
Ketamine | NMDA antagonist | 0.3–100 | i.p. | Lister rat | Male | Free operant | Mixed | ↑↓rate | Herberg and Rose, 1989 | |
Ketamine | NMDA antagonist | 3.2–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Hillhouse et al., 2014 |
THC | CB1/CB2 agonist | 1.0 | i.p. | Fischer 344 rat | Male | Hybrid | Frequency | No effect | Lepore et al., 1996 | |
THC | CB1/CB2 agonist | 1.0 | i.p. | Lewis rat | Male | Hybrid | Frequency | Facilitation | ↓θ0 ↓M50 | Lepore et al., 1996 |
THC | CB1/CB2 agonist | 1.0 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Facilitation | ↓θ0 | Lepore et al., 1996 |
THC | CB1/CB2 agonist | 0.1 and 1.0 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Mixed | ↑↓EF36.7 | Katsidoni et al., 2013 |
THC | CB1/CB2 agonist | 1.0–10 | i.p. | Sprague-Dawley rat | Male | Hybrid | Frequency | Depression | ↓rate | Kwilasz and Negus, 2012 |
Caffeine | adenosine antagonist | 1.0–20 | i.p. | Wistar rat | Male | Discrete trial | Amplitude | Mixed | ↑↓CIT | Bespalov et al., 1999 |
Testosterone | anabolic steroid | 50 μg | Sherman rat | Male | Free operant | Facilitation | ↑rate | Caggiula and Hoebel, 1966 | ||
Tripelennamine | H1 antagonist | 0.625–20 | i.p. | CDF rat | Male | Discrete trial | Amplitude | Facilitation | ↓CIT | Unterwald et al., 1984 |
Rate, response rate; CIT, current-intensity threshold; θ0, theta-0 threshold; M50 or EF50, frequency maintaining 50% maximum rate; EF36.7, frequency maintaining 36.7% maximum rate.
↵a Mechanism of action or drug class.
↵b First column indicates structure of experimental session (see text for details). Second column indicates stimulation parameter under manipulation across trials.
↵c Most prominent drug effect on ICSS.